An interventional study of Snakehead Fish Powder + Bitter Melon Extract and Placebo Capsule in Type 2 Diabetes Mellitus (T2DM) and Hyperglycemia, sponsored by Universitas Muhammadiyah Surakarta. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Universitas Muhammadiyah Surakarta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed.
Previous preclinical and early clinical studies have shown that bitter melon (Momordica charantia L.) and snakehead fish (Channa striata) possess antidiabetic and anti-inflammatory properties, including improvement in glucose regulation, stimulation of insulin secretion, and regeneration of pancreatic cells. However, clinical evidence on their combined use remains limited.
This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effect of daily supplementation with a combination of bitter melon extract and snakehead fish powder on glycemic status in adults with Type 2 diabetes mellitus. Ninety eligible participants will be randomly assigned to a treatment group receiving 500 mg/day of the herbal combination or a placebo for 4 weeks. Glycemic status will be assessed primarily through glycated albumin (GA) levels.
The findings of this study are expected to provide scientific evidence regarding the safety and efficacy of this herbal combination as a complementary antidiabetic therapy.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia caused by impaired insulin sensitivity and progressive β-cell dysfunction. Long-standing hyperglycemia contributes to vascular inflammation, oxidative stress, and the formation of advanced glycation end products (AGEs), leading to complications that affect multiple organ systems including the kidneys, eyes, nerves, and cardiovascular system. The prevalence of T2DM continues to rise globally, particularly in low- and middle-income countries, resulting in a significant public health burden. Although conventional antidiabetic medications such as metformin, sulfonylureas, thiazolidinediones, and insulin effectively control blood glucose levels, long-term use may be associated with adverse effects including gastrointestinal disturbances, hypoglycemia, lactic acidosis, lipodystrophy, and contraindications in patients with hepatic or renal impairment. This situation highlights the need for safer, well-tolerated complementary approaches derived from natural products.
Bitter melon (Momordica charantia L.) has been traditionally used as a hypoglycemic agent and has demonstrated antidiabetic properties through multiple mechanisms, including reduction of glucagon secretion, inhibition of intestinal glucose absorption, enhancement of insulin release, and increased peripheral glucose uptake. Meanwhile, snakehead fish (Channa striata) is known to contain high levels of albumin, essential amino acids, and bioactive peptides that support tissue repair, modulate inflammation, and may contribute to improved pancreatic function. Preclinical studies and preliminary clinical observations suggest that these two natural ingredients possess synergistic potential in improving glycemic control, yet their combined effect has not been adequately evaluated in controlled human trials.
This study is designed as a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of a daily 500-mg supplementation of combined bitter melon extract and snakehead fish powder in improving glycemic status among adults with T2DM. A total of 90 eligible participants aged 20-65 years will be recruited from several community health centers in Surakarta, Indonesia. Participants will be randomized into intervention and placebo groups, while maintaining their standard antidiabetic therapy (metformin monotherapy). The intervention involves consuming one standardized capsule per day for four weeks. Bitter melon extract is prepared through ethanol maceration and evaporation, whereas snakehead fish powder is produced by steaming, drying, pulverizing, and sieving. Standardized nutrient and phytochemical analyses are conducted to ensure batch consistency and quality.
Glycemic control will be assessed primarily through measurements of glycated albumin (GA), which offers greater sensitivity to short-term glycemic fluctuations compared to HbA1c, and is particularly relevant for patients with variable glucose levels. Fasting plasma glucose will also be evaluated as a secondary outcome. Blood samples will be collected at baseline and at the end of week four. Statistical analyses will include paired t-tests for intragroup comparisons and independent t-tests for between-group comparisons, with significance set at p \< 0.05.
This study is expected to generate scientific evidence on the efficacy and safety of the combined bitter melon-snakehead fish supplement as a complementary therapy for T2DM. The findings may contribute to the development of herbal-based antidiabetic products, support future patent applications, and provide a foundation for larger clinical trials aimed at improving accessible and culturally relevant diabetes management strategies.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's planned enrollment of 80 is close to the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Universitas Muhammadiyah Surakarta is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the experimental group will receive a combined herbal supplement containing Channa striata (snakehead fish) powder and Momordica charantia L. (bitter melon) extract. The supplement is provided in capsule form containing 500 mg per day, administered for 4 weeks.
Dietary Supplement: Snakehead Fish Powder + Bitter Melon Extract
Participants in the control group will receive placebo capsules identical in appearance, administered once daily for 4 weeks, with no active herbal ingredients
Other: Placebo Capsule
Drug page: Bitter melon extractStudies of Bitter melon extractBitter melon extract pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
A 500 mg/day capsule containing a combination of: * Channa striata (snakehead fish) powder * Momordica charantia (bitter melon) ethanol extract Administered orally once daily for 4 weeks
Capsule identical in size, shape, and color to the intervention capsule, without active ingredients. Administered orally once daily for 4 weeks.
Change in Fasting Plasma Glucose (FPG) Level
Fasting plasma glucose level measured at baseline (week 0) and after 4 weeks of supplementation with the combination of Channa striata (snakehead fish powder) and Momordica charantia (bitter melon extract), compared with placebo.
Time frame: Baseline and Week 4
No study locations are listed for this record.
Plan to share: No — Individual participant data (IPD) will not be shared because the study involves a limited sample size and contains sensitive clinical information. Data access is restricted to protect participant confidentiality and is limited to the research team as approved by the institutional ethics committee.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Feb 2026, 1 month later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 1 month is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bitter melon extract
Universitas Muhammadiyah Surakarta